Many companies are trying to establish a foothold in mRNA technology, but few have yet to achieve the necessary scale, or the capabilities in research and development, of front-runners such as Moderna or BioNTech, says Andy Acker of Janus Henderson. Of the two, is probably the purest play as it
Five of the most promising stocks
Apr 19, 2024
2 minutes
You’re reading a preview, subscribe to read more.
Start your free 30 days